Randomized controlled trial testing intravenous esketamine for perioperative depressive symptoms in Parkinson's disease patients, assessing efficacy and safety.

Provides clinically actionable repurposing evidence for managing perioperative depression in PD—relevant for symptom control and perioperative outcomes—but offers limited insight into disease‑modifying mechanisms or core PD biology.